Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2974 - French real-life efficacy of 1st line gefitinib in EGFR mutation-positive NSCLC in the prospective EPIDAURE study: Results by EGFR exon 19 Del and L858R mutation subtypes


08 Oct 2016


Poster Display


Maurice Perol


Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383


M. Perol1, J. Morère2, E. Fabre3, B. Lemaire4, I. Monnet5, E. Brambilla6, V. Rondeau7, M. Licour8, J. Cadranel9

Author affiliations

  • 1 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 2 Medical Oncology, Hopital Paul Brousse, Villejuif/FR
  • 3 Medical Oncology, Hopital Europeen Georges, Paris/FR
  • 4 Pneumologie, C.H.R. Orleans - La Source, Orleans/FR
  • 5 Pulmonology, Respiratory Medicine, Oncology, CHI de Créteil,, Créteil/FR
  • 6 Department Of Pathology, Hôpital Albert Michallon, Tronch/FR
  • 7 Isped, Inserm U1219, Université de Bordeaux, Bordeaux/FR
  • 8 Department Of Epidemiology And Biometry, AstraZeneca, Courbevoie/FR
  • 9 Pneumology, Hôpital Tenon, 75020 - Paris/FR


Abstract 2974


The EGFR tyrosine kinase inhibitor (TKI) gefitinib (IRESSATM) received approval in France on 4 Nov 2009. At the French authority's request, the EPIDAURE study was initiated in Jan 2012 to explore real-life gefitinib use in terms of patients (pts) population, EGFR mutation testing and efficacy.


Eligible French pts had NSCLC of any stage, histology or treatment line, and started gefitinib treatment between Jan 2011-Mar 2013 prior to study entry (‘prevalent pts’) or at study entry (‘incident pts’). Efficacy, safety and quality of life with gefitinib were assessed over a 2-year follow-up period (previously reported: ELCC 2016 #327). Efficacy data (objective response rate [ORR], progression-free survival [PFS], overall survival [OS]) in pts with EGFR common mutation-positive NSCLC who received 1st line gefitinib are presented by mutation subtype.


Of 361 pts recruited across 104 sites in France (116 incident pts), 283 were EGFR mutation-positive and received 1st line gefitinib (94 incident pts); EGFR mutation subtypes data were available for 260 (82 incident pts). Median duration of follow-up: 20.8 months. In the total 1st line population: median age was 71 years, 61% were never-smokers, 73% had performance status 0-1 and 33% had brain metastases. ORR was 68.5% (95% CI 61.9, 72.9), median PFS was 11.5 months (95% CI 10.0, 13.4) and median OS from initiation of gefitinib was 25.7 months (95% CI 23.4, 27.9). Better outcomes were observed with exon 19 Del vs L858R mutations (Table), especially in incident pts.


EPIDAURE provided a large cohort of French pts with EGFR mutation-positive NSCLC treated with 1st line gefitinib. Higher ORR and prolonged OS/PFS in exon 19 Del vs L858R mutations indicate that this subtype represents distinct tumours which may be more sensitive to EGFR TKI therapy. Findings were similar to afatinib data in Caucasian pts. Funding AstraZeneca.

Incident pts (n = 82) Total pts (n = 260)
Exon 19 del L858R Exon 19 del L858R
EGFR mutation subtype, n (%) 49 (60) 29 (35) 136 (52) 106 (41)
ORR, n (%) (95% CI) 39 (83) (72.3, 93.7) 16 (59) (40.8, 77.8) 102 (78) (70.8, 85.0) 66 (64) (54.8, 73.4)
PFS, median months (95% CI) 12.2 (9.1, 18.1) 6.4 (5.3, 10.5) 12.8 (10.2, 14.9) 11.0 (7.7, 13.4)
OS, median months (95% CI) 27.2 (24.0, NC) 18.1 (10.9, 26.4) 31.4 (25.6, 34.6) 19.6 (16.9, 24.2)

CI, confidence interval; EGFR, epidermal growth factor receptor; NC, non-calculable; OS, overall survival; PFS, progression-free survival

Clinical trial identification

Legal entity responsible for the study





M. Perol, J-F. Morère, J. Cadranel: Honoraria received from Astra Zeneca (Advisory Board) M. Licour: Employee of AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings